📊 EDSA Key Takeaways
Is Edesa Biotech, Inc. (EDSA) a Good Investment?
Edesa Biotech is a pre-revenue pharmaceutical company with severe profitability challenges, posting zero revenue and negative net income of $2.2M. While the company maintains a strong cash position of $12.1M and minimal debt, the deteriorating cash burn rate (-$2.1M operating cash flow) and consistent operating losses indicate the business has not yet achieved viability and faces significant execution risk.
Edesa Biotech remains a pre-revenue company with ongoing operating losses and negative free cash flow, so the core fundamental profile is still weak. Its balance sheet is a clear offset, with substantial cash, very high liquidity, and no meaningful debt, which supports near-term funding flexibility. Overall, the company appears financially stable in the short run but lacks demonstrated revenue generation or durable profitability trends.
Why Buy Edesa Biotech, Inc. Stock? EDSA Key Strengths
- Strong liquidity position with $12.1M in cash and 16.82x current ratio, providing runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk
- Stable stockholders' equity of $14.0M providing buffer against losses
- Strong liquidity with $12.10M in cash and current ratio of 16.82x
- Debt-free balance sheet with low liabilities relative to equity
- Net loss improved year over year, indicating some expense discipline
EDSA Stock Risks: Edesa Biotech, Inc. Investment Risks
- Zero revenue generation indicates product commercialization failure or pre-launch phase with uncertain timelines
- Negative operating cash flow of -$2.1M annually with no revenue indicates unsustainable burn rate and eventual cash depletion
- Deteriorating profitability with worsening net income (-16.5% YoY) and EPS (-58.3% YoY) suggests accelerating losses
- High insider activity (10 Form 4 filings in 90 days) may indicate stock liquidation or confidence concerns
- No revenue generation, making the business dependent on external financing or existing cash reserves
- Continued negative operating cash flow and free cash flow indicate ongoing cash burn
- Weak growth quality due to the absence of commercial traction and recurring losses
Key Metrics to Watch
- Quarterly revenue progression and pipeline advancement milestones
- Monthly cash burn rate and projected runway before insolvency
- Operating cash flow trend and path to cash flow breakeven
- R&D efficiency and clinical trial progression for pipeline assets
- Quarterly cash burn versus cash balance
- Progress toward revenue generation or commercialization milestones
Edesa Biotech, Inc. (EDSA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.82x current ratio provides a solid financial cushion.
EDSA Profit Margin, ROE & Profitability Analysis
EDSA vs Healthcare Sector: How Edesa Biotech, Inc. Compares
How Edesa Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Edesa Biotech, Inc. Stock Overvalued? EDSA Valuation Analysis 2026
Based on fundamental analysis, Edesa Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Edesa Biotech, Inc. Balance Sheet: EDSA Debt, Cash & Liquidity
EDSA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Edesa Biotech, Inc.'s revenue has declined by 74% over the 5-year period, indicating business contraction. The most recent EPS of $-1.93 indicates the company is currently unprofitable.
EDSA Revenue Growth, EPS Growth & YoY Performance
EDSA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$1.7M | N/A |
| Q2 2021 | N/A | -$1.5M | N/A |
| Q1 2021 | N/A | -$1.1M | N/A |
| Q3 2020 | $500 | -$1.3M | N/A |
| Q2 2020 | N/A | -$455.6K | N/A |
| Q1 2020 | N/A | -$347.1K | N/A |
| Q2 2019 | N/A | -$392.3K | N/A |
| Q1 2019 | $20.5K | -$1.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Edesa Biotech, Inc. Dividends, Buybacks & Capital Allocation
EDSA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Edesa Biotech, Inc. (CIK: 0001540159)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EDSA
What is the AI rating for EDSA?
Edesa Biotech, Inc. (EDSA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EDSA's key strengths?
Claude: Strong liquidity position with $12.1M in cash and 16.82x current ratio, providing runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk. ChatGPT: Strong liquidity with $12.10M in cash and current ratio of 16.82x. Debt-free balance sheet with low liabilities relative to equity.
What are the risks of investing in EDSA?
Claude: Zero revenue generation indicates product commercialization failure or pre-launch phase with uncertain timelines. Negative operating cash flow of -$2.1M annually with no revenue indicates unsustainable burn rate and eventual cash depletion. ChatGPT: No revenue generation, making the business dependent on external financing or existing cash reserves. Continued negative operating cash flow and free cash flow indicate ongoing cash burn.
What is EDSA's revenue and growth?
Edesa Biotech, Inc. reported revenue of $0.0.
Does EDSA pay dividends?
Edesa Biotech, Inc. does not currently pay dividends.
Where can I find EDSA SEC filings?
Official SEC filings for Edesa Biotech, Inc. (CIK: 0001540159) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EDSA's EPS?
Edesa Biotech, Inc. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EDSA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Edesa Biotech, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EDSA stock overvalued or undervalued?
Valuation metrics for EDSA: ROE of -16.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EDSA stock in 2026?
Our dual AI analysis gives Edesa Biotech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EDSA's free cash flow?
Edesa Biotech, Inc.'s operating cash flow is $-2.1M, with capital expenditures of $0.0.
How does EDSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -16.1% (avg: 15%), current ratio 16.82 (avg: 2).